No Data
No Data
H.C. Wainwright Maintains VYNE Therapeutics(VYNE.US) With Buy Rating, Maintains Target Price $4.5
H.C. Wainwright Maintains VYNE Therapeutics(VYNE.US) With Buy Rating, Cuts Target Price to $4.5
LifeSci Capital Maintains VYNE Therapeutics(VYNE.US) With Buy Rating, Maintains Target Price $6
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)
HC Wainwright & Co. Maintains Buy on VYNE Therapeutics, Lowers Price Target to $4.5
Optimistic Buy Rating for VYNE Therapeutics Amid Clinical Challenges and Promising Developments